Skip to content

We are the oldest registered charity in England/Wales as well as the oldest in Scotland who are here to support those who are affected with Alpha-1 Antitrypsin Deficiency. Not only do we support those affected, their families and friends, we also bring awareness of the condition to medical professionals and the general public. Our charity is run by non-paid volunteers who are either affected by Alpha-1 or have a family member who is. We have a real passion for the charity and for supporting people who are affected, their families and friends.

We produce booklets which people can view and download digitally and even request that a set be sent to them in the post for free (UK residents only)Click here to go to our booklet area on our main website.

While we have a website (, we created this website so that people can see news about Alpha-1 from around the world in a quick and easy way.
If you would like to ask us a question about Alpha-1, you can use the 'Contact Us' form.

Charity News

New promotion, New Board Member and New website!

We at Alpha-1 Awareness have some wonderful news that we would like to share with you. Internal Promotion Glyn Cockaday joined our charity

The sad passing of Dawn Haywood- Jones

It is with great sadness that we have to write about the sad passing of Dawn Haywood- Jones. Dawn along with 3 other

Alpha-1 Awareness donates £10,000 to the research of a cure

Alpha-1 Awareness is dedicated to contributing a minimum of 10% of its funds raised towards research to find a cure for this condition.

Alpha-1 in the Press

Culver coach back on sidelines, thanks to transplant

Culver High School’s head football coach, Shea Little, has led the Bulldogs to the best record of any high school football team on

Woman in need of a double lung transplant says she’s running out of time and blames a change in American policy

SHAPLEIGH (WGME) — A woman in need of a double lung transplant says she’s running out of time and blames a change in

Mother writes book about her life as an Alpha

More than 30 years ago, a little girl from Windham in need of a liver transplant captured the hearts of Mainers. In the

Other Alpha-1 Group’s News

Research Priorities in Alpha-1 antitrypsin deficiency (AATD)

We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input

CSL Behring employees ride with Alpha-1 Foundation Team for Escape to the Cape.

Two dozen CSL Behring employees are pedaling the highways and byways of Cape Cod, Massachusetts, this weekend as part of the Alpha 1

Alpha-1 Foundation earns highest not-for-profit accreditations

The Alpha-1 Foundation earned the 2019 Platinum Seal of Transparency, the highest level of recognition offered by GuideStar, the world’s largest database and




General Research

Research Priorities in Alpha-1 antitrypsin deficiency (AATD)

We need your help! Being led by the European Alpha-1 Research Collaboration (EARCO), a survey has been created to give us all input

Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic

‘Smart Shirts’ Measuring Daily Lung Function May Help Monitor COPD, Other Respiratory Conditions

Shirts with smart technology could be used in place of traditional laboratory equipment to measure lung function, and prove to be particularly useful

Treatment Research & Trials

Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

LEXINGTON, Mass.–(BUSINESS WIRE)–Dec. 17, 2019– Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

Rehovot, Israel, December 16, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today that the first patient has

Vertex hits a biomarker bump on road to new drug

Vertex may have misjudged the data that regulators will want to see before approving one of the company’s most prized pipeline drugs. On


CSL Behring lift their precautionary distribution hold on ZEMAIRA®

The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of

Diplomat signs exclusive practice-based infusion agreement with Allergy Partners

FLINT, Mich., Aug. 8, 2019 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office

CSL Behring initiates voluntary recall for 4 lots of Zemaira

The Alpha-1 Foundation was informed by CSL Behring that a Voluntary Biological Product Recall is being initiated for 4 lots of Zemaira®, their




Help and Advice

European Lung Foundation advise on planning a flight

ELF (European Lung Foundation) has produced a poster to help make people with lung conditions aware of the steps they should take when

Other Articles

Michigan becomes first state to ban flavored e-cigarettes

Michigan becomes the first state to ban flavored e-cigarettes for minors starting today. Governor Gretchen Whitmer has been making a push to get nicotine out

First U.S. death caused by vaping confirmed in Illinois

The first reported death tied to vaping in the United States was confirmed on Friday by officials from the Illinois Department of Public Health.

Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life

Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA Abstract: Chronic physical illness is associated with significant vulnerability

© 2019 Alpha-1 Awareness